Balance Sheet
Cash Flow Statement
Amortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Operations: 2018-2024

Historic Cash from Operations for Legend Biotech (LEGN) over the last 7 years, with Dec 2024 value amounting to -$178.1 million.

  • Legend Biotech's Cash from Operations rose 186.65% to $50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$170.1 million, marking a year-over-year decrease of 7.91%. This contributed to the annual value of -$178.1 million for FY2024, which is 59.48% up from last year.
  • Latest data reveals that Legend Biotech reported Cash from Operations of -$178.1 million as of FY2024, which was up 59.48% from -$439.5 million recorded in FY2023.
  • In the past 5 years, Legend Biotech's Cash from Operations registered a high of -$178.1 million during FY2024, and its lowest value of -$439.5 million during FY2023.
  • Moreover, its 3-year median value for Cash from Operations was -$210.0 million (2022), whereas its average is -$275.9 million.
  • Per our database at Business Quant, Legend Biotech's Cash from Operations crashed by 180.85% in 2020 and then soared by 59.48% in 2024.
  • Legend Biotech's Cash from Operations (Yearly) stood at -$233.3 million in 2020, then climbed by 14.47% to -$199.5 million in 2021, then dropped by 5.27% to -$210.0 million in 2022, then slumped by 109.23% to -$439.5 million in 2023, then skyrocketed by 59.48% to -$178.1 million in 2024.